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Abstract
Introduction: A real world clinical study was designed and conducted to evaluate the performance of a novel point-of-care device for determinati-
on of glycated haemoglobin A1c (HbA1c), A1C EZ 2.0, in daily clinical practice.
Materials and methods: Five hundred and fourteen subjects were included in this study, and divided into three groups. HbA1c was measured by 
A1C EZ 2.0 and three different high performance liquid chromatography (HPLC) devices: Bio-Rad Variant II Turbo, Tosoh HLC-723 G8 and Premier 
Hb9210 separately. Precision of A1C EZ 2.0 was also evaluated.
Results: Results obtained from A1C EZ 2.0 and all HPLC devices are correlated. Passing-Bablok regression analysis shows the equation of A1C EZ 2.0 
results against the mean of HPLC devices with corresponding 95% confidence intervals (95% CI) for the intercept and slope is y = 0.10 (- 0.17 to 0.10) 
+ 1.00 (1.00 to 1.04) x. Bland-Altman difference plot shows that the mean relative difference between A1C EZ 2.0 and Variant II Turbo, G8, Hb9210 
and all HPLC results is 2.5%, 0.6%, 0.4% and 1.1%, respectively. In addition, 121 pairs of results determined by using both venous and capillary blood 
prove that the difference of two kinds of blood sample causes no notable variation when measured by A1C EZ 2.0. Precision study gives 2.3% and 
1.9% of total coefficient of variation for normal and abnormal HbA1c sample in A1C EZ 2.0.
Conclusions: HbA1c values measured by A1C EZ 2.0 were in good accordance with the results obtained with the reference HPLC devices.
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Introduction
Diabetes mellitus (DM) has become a cause of seri-
ous concern worldwide, as well as in China. The 
prevalence of DM and pre-diabetes among adult 
Chinese population in 2010 was estimated to be 
11.6% and 50.1%, respectively, representing 113.9 
and 493.4 million people. However, only 28.4% of 
DM patients have been diagnosed till now in Chi-
na (1). This implies that over eighty million patients 
with undiagnosed DM still need to be screened 
and diagnosed, which can be a major challenge 
for the public health system of China. Glycated 
haemoglobin A1c (HbA1c) values, which can reflect 
the average blood glucose concentration over the 
past 90-120 days, is now not only a standard index 
for evaluating the effectiveness of treatment, but 
also a widely acknowledged parameter for screen-
ing and diagnosing DM (2-4). High performance 
liquid chromatography (HPLC) is currently widely 
used for HbA1c measurement in clinical practice, 
but it is generally used in the hospital central labo-
ratory, where physician and patients have to wait 
for 1-3 days for getting the test results. Point-of-
Biochem Med (Zagreb) 2018;28(2):020705  https://doi.org/10.11613/BM.2018.020705 
2
Wang Y. et al.  Performance assessment of A1C EZ 2.0
care (POC) HbA1c devices, which can provide test 
results within few minutes, is fast becoming a tool 
for the screening and diagnosis of DM at a relative-
ly lower cost. Clinical studies have shown that POC 
devices help doctors in making timely adjust-
ments in treatment plan, which further brings ad-
ditional benefits to long-term glycaemic control 
(5-7). On the other hand, there were common con-
cerns about the accuracy and precision of POC 
HbA1c devices. Lenters-Westra et al. have studied 
the performance of eight POC HbA1c devices in 
2009, and only two of them met the generally ac-
cepted performance criteria (8). Most of POC HbA1c 
devices in the study failed to achieve the total CV of 
3%, and show notable differences of analytical per-
formance between different reagent lots. A similar 
investigation of seven POC HbA1c devices has been 
performed by the same authors in 2014 (9). Gener-
ally, significant improvement has been found in 
precision and accuracy of these devices, four of 
seven devices met the generally accepted perfor-
mance criteria, though some specific problems, 
such as interferences or choice of reference device 
for calibration has been found in this study (9). 
Here, we performed systematic evaluation of a 
novel hand-held HbA1c POC device, A1C EZ 2.0 (Bi-
ohermes, Wuxi, China; measurement range 4~14% 
HbA1c) in a clinical study by comparison to HPLC 
instruments. Zhou et al. reported a study of A1C EZ 
2.0 when our investigation was in progress, and 
their results show this device has favourable per-
formances (10). In order to minimize the potential 
random bias caused by a definite reference device, 
three HPLC instruments were involved in our 
study, and their mean result for each sample, as 
well as test results by individual HPLC instruments, 
were used as reference values for comparison. Lin-
ear regression analysis, bias plot, as well as sensi-
tivity and specificity analysis of A1C EZ 2.0 were 
performed based on the data obtained in the 
comparison study. In addition, the precision of A1C 
EZ 2.0 was also evaluated in this study. All instru-
ments used in this study were certified by both 
the National Glycohemoglobin Standardization 
Program (NGSP) and the International Federation 




We performed an analytical verification study of 
the POC HbA1c device A1C EZ 2.0 by comparison 
with three other IFCC certified secondary refer-
ence method (SRM) HPLC instruments. Blood sam-
ples were collected from subjects in hospital, and 
the study lasted for seven months (detail informa-
tion of instruments and subjects are given below).
Both venous and fingertip blood samples were 
used in the comparison, to investigate the test re-
sults difference between A1C EZ 2.0 and three 
HPLC instruments. Potential difference of test re-
sults caused by sample types was also studied by 
testing both venous and fingertip blood from the 
same subjects in the same instrument in this study. 
We also evaluated the precision of A1C EZ 2.0 fol-
lowing CLSI EP5-A2 (Evaluation Of Precision Per-
formance Of Quantitative Measurement Methods. 
Approved Guideline - Second Edition). Two potas-
sium-ethylenediaminetetraacetic acid (K2-EDTA) 
anticoagulant whole blood samples (one within 
normal range and the other in the higher range of 
HbA1c values) were tested in two runs per day in 
duplicate on twenty consecutive days. Controls 
provided by manufacturers were used before and 
after every day’s experiments to ensure that per-
formance of all instruments meets the required 
standards by manufacturers. Otherwise calibra-
tion was carried out following manufacturers’ 
manual.
Subjects
After approval from the institutional review com-
mittee of Shanghai Jiao Tong University Affiliated 
Sixth People's Hospital (Shanghai, China), and in ac-
cordance with the principles of the Helsinki Declara-
tion II, we randomly recruited 514 subjects from the 
Outpatient Departments of the Endocrinology and 
Metabolism of Shanghai Jiao Tong University Affili-
ated Sixth People's Hospital. We included both dia-
betes and non-diabetes cases aged fourteen and 
older. We excluded specimens from subjects with 
anaemia, haemolytic disease, red cell cycle abnor-
malities, nephropathy and other known comorbidi-
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ties, whose diseases were reported through a ques-
tionnaire survey or determined by relevant labora-
tory results. Subjects aged 60 (15 - 93) were enrolled 
from April to October 2016. Median age of male and 
female subjects was 61 and 60, respectively. 
All subjects have signed informed consent before 
their blood sample being collected. Subjects were 
divided into three groups, venous blood samples 
were collected from 197 subjects (subject group I, 
SGI), fingertip capillary whole blood samples were 
collected from other 196 subjects (subject group II, 
SGII), and both venous blood samples and fingertip 
capillary whole blood samples were collected from 
the rest 121 subjects (subject group III, SGIII). 
Sample collection 
All venous blood samples were collected in the 
standard tube (3mL, WeiGao Group, China) con-
taining K2-EDTA anticoagulant, stored at 4 °C and 
then tested within 24 hours of collection. One 
tube of venous blood sample was collected from 
each subject in SG I and SG III. For subjects in SG II, 
the fingertip capillary whole blood samples were 
directly used for the tests by A1C EZ 2.0, fingertip 
capillary whole blood samples were also collected 
in one mini tube containing K2-EDTA anticoagu-
lant and tested with three the HPLC devices within 
24 hours. 
Methods
The HbA1c values from each blood sample were 
measured by A1C EZ 2.0 and all three HPLC devices: 
Bio-Rad Variant II Turbo (Bio-Rad Laboratories, Her-
cules, USA; measurement range 3.5 - 19% HbA1c), 
Tosoh HLC-723 G8 (Tosoh, Tokyo, Japan; measure-
ment range 4 - 16.9% HbA1c) and Premier Hb9210 
(Trinity Biotech, Bray, Ireland; measurement range 
3.7 - 18.5% HbA1c). Both A1C EZ 2.0 and Premier 
Hb9210 utilize boronate affinity method; however, 
A1C EZ 2.0 uses lateral chromatography on a porous 
membrane matrix, while Premier Hb9210 HPLC de-
vice uses column chromatography. Tosoh HLC-723 
G8 and Bio-Rad Variant II Turbo devices utilize cati-
on-exchange method. All tests were performed ac-
cording to the manufacturers’ instructions manual. 
Operators performing tests on the A1C EZ 2.0 and 
HPLC devices were blinded to the clinical character-
istics of the subjects.
Statistical analysis
Linear regression analysis
Passing-Bablok linear regression analysis of HbA1c 
values obtained by A1C EZ 2.0 versus three HPLCs 
was further conducted to assess the accuracy of 
A1C EZ 2.0 while considering the above mentioned 
HPLC devices as references (11). The linear regres-
sion analysis in each subject group was performed 
separately. Six hundred and thirty-five pairs of 
data from all 514 subjects (121 subjects tested 
both venous blood and fingertip capillary whole 
blood) were also combined for linear regression 
analysis for each reference HPLC device. Finally, to 
check overall agreement independent of chosen 
reference HPLC device, the mean HbA1c values of 
three HPLC devices (referred as “mean SRM” be-
low) were used to perform the linear regression 
against results given by A1C EZ 2.0.
Bias plot, absolute value of relative difference and 
mean absolute value of relative difference
Bland-Altman difference plot was performed to 
evaluate the difference between the HbA1c values 
given by A1C EZ 2.0 and HPLC devices (12). Mean 
difference as well as the mean relative difference 
between A1C EZ 2.0 results and each HPLC results 
were calculated. The limits of agreement for the 
difference between A1C EZ 2.0 and each HPLC de-
vice were also calculated to reflect the distribution 
of these differences. In addition, the absolute val-
ue of relative difference (ARD) analysis and mean 
absolute value of relative difference (MARD) analy-
sis was performed. Absolute value of relative dif-
ference and MARD were calculated by using the 
following equations:
ARD = ( |A1C EZ 2.0 value – HPLC value| / HPLC val-
ue) × 100%
MARD = Average (ARD).
The distribution of the difference was further ana-
lysed based on the data of ARD and MARD. Six 
hundred and thirty-five pairs of data from all 514 
subjects were combined and used for bias plot, 
ARD and MARD analysis.
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Precision
Precision of A1C EZ 2.0 was evaluated using CLSI 
EP5-A2. The calculation of within-run, between-
run, within-day and total coefficient of variance 
was followed by the standard method provided in 
CLSI EP5-A2.
Comparison of venous blood results and fingertip 
capillary whole blood results
Values of 121 pairs of venous blood and fingertip 
capillary whole blood on A1C EZ 2.0 were com-
pared by Passing-Bablok linear regression analysis, 
to see if there is a significant difference between 
the two kinds of blood samples. 
Sensitivity and specificity analysis
Sensitivity and specificity were calculated by using 
HbA1c clinical decision limit for DM diagnosis of 
6.5% and mean SRM or Premier Hb9210 as refer-
ence value. MedCalc (Ostend, Belgium) statistical 




A total of 514 subjects, including 266 men and 248 
women, were randomly recruited in this study. 
The venous and fingertip capillary whole blood 
were tested in the SGI (N = 197) and SGII (N = 196) 
group, respectively. SGIII (N = 121) subjects had 
evaluations of both venous blood and fingertip 
capillary whole blood. 
The frequency distribution patterns of HbA1c val-
ues for all four instruments were similar (Figure 1). 
HbA1c values of all subjects ranged from 4.4 - 13.0% 
for A1C EZ 2.0 and from 4.5 - 13.6% for mean SRM, 
i.e. mean of all three HPLC devices. Median (95% 
confidence intervals, CIs) HbA1c of A1C EZ 2.0 was 
6.9% (6.7 - 7.0), and 6.7% (6.6 - 6.9) for all three 
HPLC devices put together (mean SRM) (Table 1).
A1C EZ 2.0 Bio-Rad VARIANT-II Tosoh HLC-723 G8 Premier HB9210 Mean SRM













KS test P < 0.001 P < 0.001 P < 0.001 P < 0.001 P < 0.001


















KS test - Kolmogorov-Smirnov test for normal distribution. Skewness coefficients and Kurtosis coefficients were used for normal 
distribution determination. SRM - secondary reference method.
Table 1. HbA1c results for all the devices investigated
Figure 1. Frequency distribution of the HbA1c values mea-
sured by the A1C EZ 2.0 and three secondary reference meth-
ods based on HPLC methodology including Bio-Rad Variant II 
Turbo, Tosoh HLC-723 G8 and Premier Hb9210. Distribution of 
mean SRM is also included in the figure. In total, 635 samples 
were analyzed by each instrument. The population percentage 




















A1C EZ 2.0 results
Bio-Rad VARIANT-II results
Tosoh HLC-723 G8 results
Premier HB9210 results
mean SRM results
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Comparison of A1C EZ 2.0 vs. Bio-Rad VARIANT-II
Passing-Bablok regression equation, 
y = a (95% CI) + b (95% CI) x
Mean difference
(limits of agreement)
Mean relative difference, %
(limits of agreement)
All subjects y = 0.03 (- 0.14 to 0.20) + 1.02 (1.00 to 1.05) x 0.17(- 0.52 - 0.85)
2.5
(- 7.3 - 12.4)
SGI (venous group) y = 0.30 (- 0.12 to 0.30) + 1.00 (1.00 to 1.06) x 0.24(- 0.41 - 0.89)
3.4
(- 5.4 - 12.2)
SGII (capillary group) y = - 0.36 (- 0.65 to 0.10) + 1.06 (1.00 to 1.10) x 0.06(- 0.64 - 0.75)
0.7
(- 8.5 - 10.0)
SGIII (for venous) y = - 0.10 (- 0.39 to 0.30) + 1.06 (1.00 to 1.10) x 0.24(- 0.36 - 0.83)
3.8
(- 5.1 - 12.7)
SGIII (for capillary) y = 0.20 (- 0.33 to 0.20) + 1.00 (1.00 to 1.09) x 0.16(- 0.58 - 0.90)
2.7
(-8.9 - 14.2)
Comparison of A1C EZ 2.0 vs. Tosoh HLC-723 G8 
All subjects y = - 0.12 (- 0.27 to 0.00) + 1.02 (1.00 to 1.05) x 0.04(- 0.57 - 0.66)
0.6
(- 8.0 - 9.2)
SGI (venous group) y = 0.10 (0.04 to 0.10) + 1.00 (1.00 to 1.02) x 0.09(- 0.51 - 0.69)
1.3
(- 6.6 - 9.3)
SGII (capillary group) y = - 0.46 (- 0.76 to 0.00) + 1.06 (1.00 to 1.11) x - 0.04(- 0.72 - 0.65)
- 0.6
(- 9.6 - 8.4)
SGIII (for venous) y = - 0.32 (0.59 to 0.10) + 1.06 (1.00 to 1.10) x 0.08(- 0.44 - 0.60)
1.1
(- 6.8 - 9.0)
SGIII (for capillary) y = - 0.20 (0.52 to 0.00) + 1.04 (1.00 to 1.09) x 0.05(- 0.52 - 0.63)
0.8
(- 8.1 - 9.7)
Comparison of A1C EZ 2.0 vs. Tosoh HLC-723 G8 Premier HB9210
All subjects y = 0.00 (- 0.00 to 0.00) + 1.00 (1.00 to 1.00) x 0.02(- 0.57 - 0.61)
0.4
(- 7.3 - 8.2)
SGI (venous group) y = 0.22 (0.00 to 0.43) + 0.97 (0.94 to 1.00) x - 0.05(- 0.67 - 0.56)
- 0.4
(- 8.0 - 7.2)
SGII (capillary group) y = 0.00 (- 0.25 to 0.00) + 1.00 (1.00 to 1.04)x 0.00(- 0.64 - 0.65)
0.2
(- 7.8 - 8.2)
SGIII (for venous) y = - 0.29 (- 0.54 to - 0.10) + 1.06 (1.00 to 1.10) x 0.11(- 0.34 - 0.56)
1.6
(- 5.4 - 8.6)
SGIII (for capillary) y = - 0.37 (- 0.64 to - 0.11) + 1.07 (1.02 to 1.11) x 0.07(- 0.44 - 0.58)
1.0
(- 6.7 - 8.8)
Comparison of A1C EZ 2.0 vs. mean SRM 
All subjects y = 0.10 (- 0.17 to 0.10) + 1.00 (1.00 to 1.04) x 0.08(- 0.50 - 0.65)
1.1
(- 6.9 - 9.2)
SGI (venous group) y = 0.10 (0.10 to 0.10) + 1.00 (1.00 to 1.00) x 0.09(- 0.48 - 0.67)
1.4
(- 6.1 - 9.0)
SGII (capillary group) y = - 0.30 (- 0.56 to 0.00) + 1.05 (1.00 to 1.08) x 0.01(- 0.63 - 0.64)
0.1
(- 8.2 - 8.4)
SGIII (for venous) y = - 0.22 (- 0.49 to 0.10)+ 1.06 (1.00 to 1.10) x 0.14(- 0.33 - 0.61)
2.1
(- 5.1 - 9.4)
SGIII (for capillary) y = - 0.23 (- 0.54 to 0.10) + 1.05 (1.00 to 1.10) x 0.09(- 0.44 - 0.63)
1.4
(- 7.0 - 9.8)
Table 2. Regression analysis of A1C EZ 2.0 results versus three secondary reference methods and the mean SRM 
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Linear regression
Linear regression analysis indicates that test re-
sults of A1C EZ 2.0 show good agreement with the 
results obtained by reference HPLC devices (Table 
2). The linear regression equation of A1C EZ 2.0 val-
ues against mean SRM is presented in Figure 2. 
A1C EZ 2.0 is most closely related to Premier 
Hb9210 of all the three reference HPLC devices. 
The slope and intercept given by linear regression 
between A1C EZ 2.0 and Premier Hb9210 with all 
of the combined data is 1.00 (1.00 to 1.00) and 0.00 
(- 0.00 to 0.00), respectively, which coincides with 
the ideal y = x function.
Bias analysis
The mean difference between A1C EZ 2.0 values 
versus mean SRM is 0.08% HbA1c (mean relative dif-
ference of 1.1%) (Figure 3 and Table 2). Respective 
mean difference for each reference HPLC device 
was 0.17% HbA1c for Bio-Rad Variant II Turbo, 0.04% 
HbA1c for Tosoh HLC-723 G8 and 0.02% HbA1c for 
Premier Hb9210 (mean relative difference of 2.5%, 
0.6% and 0.4%, respectively). All detailed statistics 
for each subject group are listed in Table 2. Bland-
Altman difference plot of A1C EZ 2.0 results vs 
mean SRM shows that 96.5% of results have rela-
tive differences from - 6.9% to 9.2% (Figure 3). In 
addition, 84.6% of data has ARD lower than 6%, 
and 94.2% of data has ARD lower than 8%. MARD 
of 3.26% of A1C EZ 2.0 results compared with 
mean SRM was found. 
Differences in HbA1c values depending upon 
types of blood sample
In this study, no notable difference in HbA1c values 
between venous and fingertip capillary whole 
blood of SGIII subjects was seen as measured by 
A1C EZ 2.0. Passing-Bablok regression analysis to-
wards paired data from venous and fingertip capil-
lary whole blood yielded the equation y = - 0.10 + 
1.00 x; with 95%CI of intercept - 0.10 to 0.08, and 
slope: 0.98 to 1.00, which indicates that there is no 
significant difference between HbA1c values on 
measurement with different kinds of blood sam-
ple. Also, there was no significant difference in 
Figure 2. Scatter diagram and linear regression analysis of A1C 
EZ 2.0 results versus mean SRM. The regression line (solid line), 
95% CIs (dashed lines) and the identity line (y = x, dotted line) 
are displayed. SRM- secondary reference method.
Figure 3. Bland-Altman relative difference plot shows the dif-
ferences between the paired A1C EZ 2.0 results and the mean 
SRM. Horizontal lines are drawn at the mean difference% (solid 
line) and at the limits of agreement (dashed lines). Mean rela-
tive difference of A1C EZ 2.0 results versus the mean SRM is 1.1%, 
with the limits of agreement from -6.9% to 9.2%. SRM- second-
ary reference method.
HbA1c values between venous and capillary blood 
on assessment with reference HPLC devices (Bio-
Rad Variant II Turbo: y = 0.00 (0.00 to 0.00) + 1.00 
(1.00 to 1.00) x; Tosoh HLC-723 G8: y = 0.0 (0.00 to 
0.00) + 1.0 (1.00 to 1.00) x; Premier Hb9210: y = 0.0 
(0.00 to 0.00) + 1.00 (1.00 to 1.00) x.
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HbA1c (%) mean SRM
y = 0.10 (- 0.17 to 0.10) +
1.00 (1.00 to 1.04) x;
P = 0.200; N = 635
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CV – coefficient of variation. 




A1C EZ 2.0 vs. 
Bio-Rad VARIANT-II
A1C EZ 2.0 vs. 
Tosoh HLC-723 G8
A1C EZ 2.0 vs. 
Premier HB9210
A1C EZ 2.0 vs. 
mean SRM
6.5%
Sensitivity (%) 96 95 96 96
Specificity (%) 90 96 96 93
6.3%
Sensitivity (%) 97 95 96 97
Specificity (%) 87 92 89 89
SRM- secondary reference method.
Table 4. Diagnostic sensitivity and specificity of A1C EZ 2.0 for diagnosing of diabetes
Precision
A1C EZ 2.0 showed good precision in the twenty 
days evaluation period (Table 3). The total CV is 
2.3% for low HbA1c sample (5.2% HbA1c) and 1.9% 
for high HbA1c sample (11.6% HbA1c). In addition, 
the within-run CV, between-run CV and between-
day CV all fell in the acceptable region (less than 
2%, Table 3), implying that A1C EZ 2.0 has consist-
ent performance over a certain period of time un-
der different circumstances.
Sensitivity and specificity of test by A1C EZ 2.0
We further evaluated the sensitivity and specificity 
of A1C EZ 2.0. While considering Premier Hb9210 
results as reference and HbA1c of 6.5% as clinical 
decision level for DM diagnosis, the sensitivity and 
specificity of A1C EZ 2.0 were both 96%. When 
mean SRM was used as reference, sensitivity and 
specificity of A1C EZ 2.0 were 96% and 93%, re-
spectively (Table 4).
Discussion
A large scale clinical study in the hospital setting 
was designed to evaluate the performance of a 
novel POC HbA1c device A1C EZ 2.0. Overall perfor-
mance of A1C EZ 2.0 was fairly good in our study, 
and was similar to the previously reported perfor-
mance by another study (7). What is different is 
that in this study we used the clinical specimens 
including the fingertip capillary whole blood, ve-
nous blood samples and both venous blood sam-
ples and fingertip capillary whole blood samples 
from the same participant. Analysis of our results 
indicates that A1C EZ 2.0 has smallest mean differ-
ence (0.02% HbA1c) with Premier Hb9210, and 
slightly less consistence with Tosoh HLC-723 G8 
and Bio-Rad Variant II Turbo. This might be as both 
A1C EZ 2.0 and Premier Hb9210 use boronate affin-
ity method. Boronate affinity method was proven 
to have good tolerance to some common interfer-
ence factors such as haemoglobin variants and 
certain drugs, which usually affect the HbA1c re-
sults determined by cation-exchange method 
(13,14). In this study, sample from one patient (data 
was excluded in our statistics) was found to have 
haemoglobin abnormality and both Bio-Rad Vari-
ant II Turbo and Tosoh HLC-723 G8 failed to give 
reasonable results, while Premier Hb9210 and A1C 
EZ 2.0 gave similar HbA1c value (7.6% and 7.8% 
HbA1c, respectively). For several other samples 
where the relative differences between Premier 
Hb9210 and Tosoh HLC-723 G8 or Bio-Rad Variant II 
Turbo were more than 10%, we inferred that some 
interference factors might have existed in those 
samples and Premier Hb9210 results were consid-
ered to be more reliable.
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Although venous blood may differ from capillary 
blood to some extent, in many aspects, such as to-
tal protein, blood cell concentration and ion con-
centration, the HbA1c value usually shows no nota-
ble difference when measured using different 
type of blood sample in different instruments (15-
19). There was no significant difference in HbA1c 
values between venous blood and fingertip capil-
lary whole blood of SGIII subjects as seen on meas-
urement by A1C EZ 2.0.
Sensitivity and specificity analysis of A1C EZ 2.0 in-
dicates that the risk of false positive and negative 
results is very low with evaluation by A1C EZ 2.0. 
Several former studies have shown that the ideal 
cut-off HbA1c values for diagnosis of DM varies 
among ethnic groups, and the best clinical deci-
sion level for Chinese population might be 6.3% 
(20-23). We also used 6.3% as cut-off value, and 
found that the sensitivity and specificity of A1C EZ 
2.0 was 96% and 89% as compared to Premier 
Hb9210 as reference, and 97% and 89% as com-
pared to mean SRM as reference. In this analysis, 
when clinical decision level was changed from 
6.5% to 6.3%, high sensitivity was maintained, 
whereas specificity dropped as compared to both 
references (Table 4). In conclusion, the sensitivity 
and specificity of A1C EZ 2.0 meets the general 
clinical requirement for HbA1c testing, and can be 
used for clinical diabetes diagnosis.
As the POC HbA1c devices can provide results in 
short time and at relatively lower cost, these can 
help in improving the doctor-patient interaction, 
appropriate modification of the treatment if re-
quired and/or diagnosis/screening of new cases of 
DM from large population with higher efficiency. 
On the other hand, doubts towards POC HbA1c de-
vices have been raised in some studies showing 
that some POC HbA1c devices may not be suitable 
for clinical use due to their unsatisfactory preci-
sion and/or variation in different lots (5,6). Thus, 
more precise and accurate POC HbA1c device is in 
urgent need, especially in countries like China, 
with an increasing incidence and prevalence of 
DM, as expensive HPLC HbA1c instruments are usu-
ally inaccessible and unaffordable to many grass-
roots medical institutions.
While it is widely accepted that HPLC devices rep-
resent one of the most accurate way to measure 
HbA1c, we found that performance of POC HbA1c 
device is not significantly different from the HPLC 
devices in this study. The 84.7% of Bio-Rad Variant 
II Turbo results have ARD lower than 6%, and 
94.6% have lower than 8% as compared with Pre-
mier Hb9210 results. Both values are slightly lower 
than A1C EZ 2.0 87.6% and 96.5%, respectively 
(data not shown). The controls were tested before 
and after every day’s experiments and routine cali-
brations were carried out in all HPLC devices to 
confirm that performance of all instruments were 
in the claimed acceptable region by manufactur-
ers. However, Bio-Rad Variant II Turbo results show 
consistent negative bias (about - 0.2% HbA1c) as 
compared with Tosoh HLC-723 G8, Premier 
Hb9210, A1C EZ 2.0 in our study. This negative bias 
was observed in all three subject groups and 
through seven months period of this study. Such 
kind of bias might have occurred due to the 
change of condition of cation-exchange column 
during use, or the individual calibration process 
we performed, as both are commonly seen in clini-
cal applications. On the other hand, use of POC 
HbA1c device like A1C EZ 2.0, which usually uses 
single cartridge or strip for one test can decrease 
the risk of systematic bias and might achieve simi-
lar performance as HPLC in clinical practice while 
having slightly higher CV than HPLC device at the 
same time. 
In conclusion, we verified a novel POC HbA1c device 
A1C EZ 2.0, and found its performance met the 
general clinical requirement in this study. However, 
there are still some limitations in our study. Only 
one lot of strip of A1C EZ 2.0 was used in this study, 
thus lot-to-lot variation of strips has not been eval-
uated; we also did not evaluate the stability of test 
strip of A1C EZ 2.0 in this work. Tests by A1C EZ 2.0 
and HPLC instruments were not performed at ex-
actly the same point of time. All these limitations 
merit further investigation in future.
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